Recon: FDA approves SpringWorks’ Ogsiveo for treating desmoid tumors; Pfizer sues Poland over missed COVID-19 vaccine payments

• SpringWorks wins FDA approval for drug to treat desmoid tumors (STAT)
• SpringWorks' non-cancerous tumor drug to be priced at $29,000 per month in US (Reuters)
• White House urges RSV vaccine makers to meet demand (Reuters)
• Background Music During Risk Segment Of Rx Drug Ads: FDA Explains Its Policy (Pink Sheet)
• Merck stokes pneumococcal rivalry with Pfizer, revealing updated 21-valent vaccine data (Endpoints)
• Unomedical recall of infusion sets tagged as Class I by FDA (MedTech Dive)
• Accelerated Approval Drugs’ Fate Rests Heavily On Current Therapeutic Landscape When Confirmatory Trials Are Overdue (Pink Sheet)

• Pfizer takes Poland to court over alleged missed COVID-19 vaccine payments (Fierce Pharma)
• Hospital chain Aster DM to sell majority stake in Gulf business for $1 bln (Reuters)
• WHO authorizes emergency use of Novavax’s updated COVID shot (Reuters)
• Suspected fraud on UK COVID loans climbs 7% in value -govt data (Reuters)
• El Salvador Sets Up New Regulatory Body To Oversee Medicines & Devices (MedTech Insight)
• EU Aims To Foster Innovation Through Streamlined Uptake Of Clinical Trial Methodologies (Pink Sheet)
• ACCESS Consortium Expands Focus To ATMPs And ‘Urgently Needed’ Medicines (Pink Sheet)
• The Opportunities & Challenges Of Local mRNA Vaccine Production In Africa (Pink Sheet)  

• Argenx antibody fails study in platelet-destroying autoimmune disorder, derailing expansion plans (STAT)
• Manufacturers need to be more open about a dangerous Alzheimer’s drug side effect (STAT)
• How to spot when drug companies spin clinical trial results (STAT)
• Nippon Life to buy Nichii Holdings for about $1.41 bln (Reuters)
• Novartis execs highlight progress of slimmer pipeline after Sandoz spinoff (Endpoints)
• Takeda aligns with leading rare disease group for calls to action around health equity diagnoses (Endpoints)
• Early-stage healthcare startups are facing a funding cliff (Endpoints)
• Novocure to lay off 200 workers, narrow pipeline for electric fields cancer therapy (Endpoints)
• Immunovant takes on argenx, J&J with plans to test FcRn inhibitor in multiple parallel trials after PhI win (Endpoints)
• Acelyrin says CRO Fortrea made errors in trial of lead immunology drug izokibep (Endpoints)
• Aro raises $41M; Candel’s layoffs; Lilly to expand its accelerator to San Diego (Endpoints)
• Coherus prices China-made PD-1 drug Loqtorzi at 20% discount to Merck's Keytruda (Fierce Pharma)

• Shattered Glass Or Broken Ladder: Is the Medtech Industry Becoming More Equal For Women? (MedTech Insight)
• Why medical device companies are worried about the EPA’s planned sterilization regs (MedTech Dive)
• News We’re Watching: Boston Scientific Closes Relievant, Medtronic's PFA Earns CE Mark, And More (MedTech Insight)
• Medtronic to chase Boston Scientific, Abbott in left atrial appendage closure market (MedTech Dive)

• The push to get estrogen FDA-approved for gender-affirming care (STAT)
• A growing number of U.S. states, cities, and counties are suing insulin makers and PBMs (STAT)
• Who cares about pharma ESG efforts? Patients and patient groups do — and they want more, survey finds (Endpoints)
• Teva drops patent case against Lilly after two Ajovy patents deemed invalid (Fierce Pharma)
• GSK’s consumer wing nears settlement of ‘non-drowsy’ marketing lawsuit (Fierce Pharma)